World's Best Scientists 2026 revealed!
VIEW LIST
Igor Bondarenko

D-Index & Metrics

Medicine

D-Index
77
Citations
51747
World Ranking
18228
National Ranking
3

Igor Bondarenko publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Igor Bondarenko sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 283 publications — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Igor Bondarenko D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Igor Bondarenko sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 77 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Igor Bondarenko is affiliated with the Ministry of Internal Affairs in Romania and has an extensive publication record primarily in the field of medicine, with a focus on oncology. Their work encompasses a broad range of topics in cancer research and treatment, with a particular emphasis on lung cancer and immunotherapy.

Bondarenko's research spans several main areas and subfields, including:

  • Medicine
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Genetics
  • Molecular Biology
  • Cancer Research

Their main topics of research include:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Cancer Treatment and Pharmacology
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research

Bondarenko has published multiple papers in frequent collaboration with co-authors, including Mustafa Özgüroğlu (37 joint publications), İrfan Çiçin (20), Saadettin Kılıçkap (19), Miranda Gogishvili (17), and Petra Rietschel (16). This network highlights a consistent partnership within oncology research communities.

They have contributed to several high-impact publication venues, with the most frequent being:

  • Annals of Oncology (35 publications)
  • Journal of Clinical Oncology (24 publications)
  • Journal of Thoracic Oncology (17 publications)
  • Cancer Research (11 publications)
  • Clinical Cancer Research (7 publications)

Selected recent papers authored by Bondarenko include:

  • "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial" (2021), published in The Lancet
  • "Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial" (2020), published in The Lancet Oncology
  • "Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study" (2023), published in The Lancet
  • "Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial" (2020), published in UNC Libraries
  • "Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer" (2022), published in JAMA

Best Publications

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

    Carsten Bokemeyer;Igor Bondarenko;Anatoly Makhson;Joerg T. Hartmann

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

    Richard S Finn;John P Crown;Istvan Lang;Katalin Boer

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

    Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

    Martin Reck;Rolf Kaiser;Anders Mellemgaard;Jean-Yves Douillard

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

    C. Bokemeyer;I. Bondarenko;J. T. Hartmann;F. de Braud

  • Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

    Mark A. Socinski;Igor Bondarenko;Nina A. Karaseva;Anatoly M. Makhson

  • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

    M. Reck;I. Bondarenko;A. Luft;P. Serwatowski

  • Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

    Angelo Di Leo;Guy Jerusalem;Lubos Petruzelka;Roberto Torres

  • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

    G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

  • Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

    Ahmet Sezer;Saadettin Kilickap;Mahmut Gümüş;Igor Bondarenko

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Claus Garbe
Claus Garbe University of Tübingen
Joachim von Pawel
Joachim von Pawel The University of Texas MD Anderson Cancer Center
Caroline Robert
Caroline Robert University of Paris-Saclay
Silvia Novello
Silvia Novello University of Turin
Jean-Yves Douillard
Jean-Yves Douillard European Society for Medical Oncology
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Jifeng Feng
Jifeng Feng Nanjing Medical University

External Links

Personal website of Igor Bondarenko

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in alternative routes into healthcare or expanding your career options, there are several online degree programs worth considering. For nurses who want to move into leadership, research, or advanced clinical roles, pursuing dnp programs online can offer a flexible pathway to the highest level of nursing practice.

Those looking for a quicker entry into the nursing field could consider fast lpn program options. These allow students to qualify as Licensed Practical Nurses in less time, providing a valuable gateway into healthcare careers.

If your passion lies in mental health, the fastest psychiatric nurse practitioner program options online can help you specialize and serve this critical area while balancing other commitments.

For those more interested in healthcare leadership and system management, exploring the healthcare administration degrees can open doors to roles in hospital administration and health policy. Online education provides flexibility and affordability, making these career transitions more accessible than ever.

Best Scientists Citing Igor Bondarenko

Jedd D. Wolchok

Jedd D. Wolchok

Cornell University

Publications: 162

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 150

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 142

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 129

Caroline Robert

Caroline Robert

University of Paris-Saclay

Publications: 128

Michael A. Postow

Michael A. Postow

Memorial Sloan Kettering Cancer Center

Publications: 102

James Larkin

James Larkin

Royal Marsden NHS Foundation Trust

Publications: 99

Reinhard Dummer

Reinhard Dummer

University of Zurich

Publications: 95

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 94

F. Stephen Hodi

F. Stephen Hodi

Harvard University

Publications: 89

Giuseppe Curigliano

Giuseppe Curigliano

University of Milan

Publications: 89

Antoni Ribas

Antoni Ribas

University of California, Los Angeles

Publications: 88

Grant A. McArthur

Grant A. McArthur

Peter MacCallum Cancer Centre

Publications: 85

Céleste Lebbé

Céleste Lebbé

Hôpitaux Universitaires Paris-Ouest

Publications: 79

Martin Reck

Martin Reck

LungenClinic Grosshansdorf

Publications: 79

Claus Garbe

Claus Garbe

University of Tübingen

Publications: 78

Trending Scientists

Mathieu Giraudeau

Mathieu Giraudeau

University of La Rochelle

Henrik Stryhn

Henrik Stryhn

University of Prince Edward Island

Laura P.W. Ranum

Laura P.W. Ranum

University of Florida

Mohsen Kavehrad

Mohsen Kavehrad

Pennsylvania State University

Stéphane Udry

Stéphane Udry

University of Geneva

Michael V. Norgard

Michael V. Norgard

The University of Texas Southwestern Medical Center

Patricia J. McLaughlin

Patricia J. McLaughlin

Pennsylvania State University

Mary Frances McMullin

Mary Frances McMullin

Queen's University Belfast

Ryuji Tada

Ryuji Tada

University of Tokyo

Junzhou Huang

Junzhou Huang

The University of Texas at Arlington

Tuti Mariana Lim

Tuti Mariana Lim

Nanyang Technological University

Mark L. Dietz

Mark L. Dietz

University of Wisconsin–Milwaukee

William Davison

William Davison

Lancaster University

Fujio Mizukami

Fujio Mizukami

National Institute of Advanced Industrial Science and Technology

Kenneth D. Burman

Kenneth D. Burman

MedStar Washington Hospital Center

Robert C. Fleischer

Robert C. Fleischer

Smithsonian Conservation Biology Institute

Related Medicine Rankings & Guides

2026 Best Occupational Therapy Programs

2026 Best Occupational Therapy Programs
2026 Most Affordable Online Dental Assistant to Dental Hygienist Bridge Programs

2026 Most Affordable Online Dental Assistant to Dental Hygienist Bridge Programs
2026 Is Grand Canyon University School of Nursing Worth It?

2026 Is Grand Canyon University School of Nursing Worth It?
2026 Best Nursing Schools in Virginia – Accredited ADN, BSN, MSN Programs

2026 Best Nursing Schools in Virginia – Accredited ADN, BSN, MSN Programs
2026 Best Online Associate in Physical Therapy Assistant Programs

2026 Best Online Associate in Physical Therapy Assistant Programs
2026 Best Shortest Online PMHNP Certificate Programs

2026 Best Shortest Online PMHNP Certificate Programs
2026 Best Online MSN Family Nurse Practitioner Programs

2026 Best Online MSN Family Nurse Practitioner Programs
2026 Best Online Nursing Programs in Maine – Accredited RN to BSN Programs

2026 Best Online Nursing Programs in Maine – Accredited RN to BSN Programs
2026 Fastest Online Nutrition Degree Programs

2026 Fastest Online Nutrition Degree Programs
2026 Fastest Online RN to MSN (No ADN Required) Bridge Programs

2026 Fastest Online RN to MSN (No ADN Required) Bridge Programs
August 2026 Best Nursing Certifications to Consider

August 2026 Best Nursing Certifications to Consider
2026 Best RN to BSN Programs With No Clinicals

2026 Best RN to BSN Programs With No Clinicals
2026 Most Affordable Online Accelerated BSN Programs for Non-Nurses

2026 Most Affordable Online Accelerated BSN Programs for Non-Nurses
2026 Most Affordable Online Licensed Practical Nurse (LPN) Programs

2026 Most Affordable Online Licensed Practical Nurse (LPN) Programs
2026 Best Online Master’s in Clinical Research Programs

2026 Best Online Master’s in Clinical Research Programs
2026 Best Nurse Practitioner Programs in Wisconsin – Accredited Schools Online & Campus

2026 Best Nurse Practitioner Programs in Wisconsin – Accredited Schools Online & Campus
2026 Most Affordable Online Medical Assistant Programs

2026 Most Affordable Online Medical Assistant Programs
2026 Best Online Medical Assistant Associate Degree Programs

2026 Best Online Medical Assistant Associate Degree Programs
2026 Fastest Doctor of Nursing Practice (DNP) Degree Programs

2026 Fastest Doctor of Nursing Practice (DNP) Degree Programs
2026 Best Nursing Schools in Texas – Accredited ADN, BSN, MSN Programs

2026 Best Nursing Schools in Texas – Accredited ADN, BSN, MSN Programs
2026 Best Online Surgical Tech Certificate Programs

2026 Best Online Surgical Tech Certificate Programs

Recently Published Articles

2026 Is a Healthcare Administration Online Degree Worth It?

2026 Is a Healthcare Administration Online Degree Worth It?
2026 How to Become a School Psychologist in Georgia - School Psychology Programs and Certifications Online & Campus

2026 How to Become a School Psychologist in Georgia - School Psychology Programs and Certifications Online & Campus
2026 MBA vs. Master's in Forensic Science: Which Drives Better Career Outcomes

2026 MBA vs. Master's in Forensic Science: Which Drives Better Career Outcomes
2026 Best Accelerated CNA to RN Online Bridge Programs

2026 Best Accelerated CNA to RN Online Bridge Programs
2026 Best Online Associate in Physical Therapy Assistant Programs

2026 Best Online Associate in Physical Therapy Assistant Programs
2026 MBA/MHA Dual Degree: ROI, Curriculum & Career Opportunities

2026 MBA/MHA Dual Degree: ROI, Curriculum & Career Opportunities
2026 Is Healthcare Administration a Hard Major? What Students Should Know

2026 Is Healthcare Administration a Hard Major? What Students Should Know
2026 Online Substance Abuse Counseling Degree Programs Costs: Tuition & Fees

2026 Online Substance Abuse Counseling Degree Programs Costs: Tuition & Fees
2026 Cheapest and Shortest Online Biology Degree Programs That Pay Well: Cost, Duration, and Salary Outlook

2026 Cheapest and Shortest Online Biology Degree Programs That Pay Well: Cost, Duration, and Salary Outlook
2026 Are There Any One-Year Online Communication Degree Programs Worth Considering?

2026 Are There Any One-Year Online Communication Degree Programs Worth Considering?
2026 Best Speech Pathology Degrees for Working Adults

2026 Best Speech Pathology Degrees for Working Adults
2026 Online Applied Psychology Degree Master's Programs That Meet State Licensure Requirements

2026 Online Applied Psychology Degree Master's Programs That Meet State Licensure Requirements
2026 Part-Time Online Speech Pathology Programs for Working Adults

2026 Part-Time Online Speech Pathology Programs for Working Adults
2026 Most Affordable Online MBA in Finance Degree Programs

2026 Most Affordable Online MBA in Finance Degree Programs
2026 Can You Get an Architecture Degree Master's Without a Related Bachelor's Degree?

2026 Can You Get an Architecture Degree Master's Without a Related Bachelor's Degree?
2026 Best AI Master's Degrees for AI Policy Careers

2026 Best AI Master's Degrees for AI Policy Careers
2026 Online Construction Management Degree Programs Costs: Tuition & Fees

2026 Online Construction Management Degree Programs Costs: Tuition & Fees
2026 Graduation Rates for Online Family Nurse Practitioner Master's Programs: Completion Statistics

2026 Graduation Rates for Online Family Nurse Practitioner Master's Programs: Completion Statistics
2026 How to Become a Mechanic in Georgia: Requirements & Certification

2026 How to Become a Mechanic in Georgia: Requirements & Certification
2026 One-Year Online Library Science Master's Degree Programs: Accelerated Options, Costs & Outcomes

2026 One-Year Online Library Science Master's Degree Programs: Accelerated Options, Costs & Outcomes
2026 How Many Credits Can You Transfer into an Applied Behavior Analysis Degree Master's Program?

2026 How Many Credits Can You Transfer into an Applied Behavior Analysis Degree Master's Program?